1. Others Metabolic Enzyme/Protease
  2. Environmental Pollutants Endogenous Metabolite
  3. Menadione

Menadione is a naphthoquinone that is converted into active vitamin K2 in the body. Menadione is a potential anticancer agent and radiosensitizer.

For research use only. We do not sell to patients.

CAS No. : 58-27-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
1 g In-stock
5 g In-stock
10 g In-stock
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 27 publication(s) in Google Scholar

Other Forms of Menadione:

Top Publications Citing Use of Products
Flow Cytometry
In Vivo Efficacy Study
Others
Cell Proliferation/Viability Assay

    Menadione purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2025 Apr;22(4):356-370.  [Abstract]

    Ectopic expression of TGM1 in Menadione (0-40 μM; 0-24 h)-treated 293 T cells was upregulated in a dose-dependent and time-dependent manner.

    Menadione purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2025 Apr;22(4):356-370.  [Abstract]

    Short-term high-dose Menadione (50 µM; 15 min) treatment also upregulated the ectopic expression of NCL in 293 T cells.

    Menadione purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 17;13(1):7031.  [Abstract]

    Menadione treatment group as a positive control. Cells were counted after treatment with Dox (1 µg/ml) or menadione (50 µM) and antioxidants for 48 h.

    Menadione purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Aug 16;12(1):4961.  [Abstract]

    Tumor growth curves are shown in the figure for KYSE30-derived tumor xenograft mouse models treated with DMSO or three drugs (GW8510, 5 mg/kg; Menadione, 10 mg/kg; suconazole, 10 mg/kg; ip; once every three days for thirty days).

    Menadione purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Aug 16;12(1):4961.  [Abstract]

    Colony formation assays were performed on KYSE30 cells by treating them with DMSO or three different drugs for 24 hours. The drugs were: Succinazole, 50 μM; Menadione, 20 μM; and GW8510, 15 μM.

    View All Endogenous Metabolite Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Menadione is a naphthoquinone that is converted into active vitamin K2 in the body. Menadione is a potential anticancer agent and radiosensitizer[1].

    IC50 & Target

    Human Endogenous Metabolite

     

    Cellular Effect
    Cell Line Type Value Description References
    A2058 IC50
    13.4 μM
    Compound: Menadione
    Cytotoxicity against human A2058 cells assessed as inhibition of formazan formation at day 5 by measuring absorbance at 430 nm
    Cytotoxicity against human A2058 cells assessed as inhibition of formazan formation at day 5 by measuring absorbance at 430 nm
    [PMID: 19969400]
    A2780 IC50
    2.6 μM
    Compound: 13
    Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay
    Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay
    [PMID: 19028102]
    A549 IC50
    15.89 μM
    Compound: VK3
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35085721]
    A549 IC50
    25.1 μM
    Compound: 18
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    DBTRG-05MG IC50
    13 μM
    Compound: Menadione
    Antiproliferative activity against human DBTRG-05MG cells assessed as inhibition of cell growth incubated for 72 hrs in presence of sodium orthovanadate by cell counting kit method
    Antiproliferative activity against human DBTRG-05MG cells assessed as inhibition of cell growth incubated for 72 hrs in presence of sodium orthovanadate by cell counting kit method
    [PMID: 38458106]
    DBTRG-05MG IC50
    22 μM
    Compound: Menadione
    Antiproliferative activity against human DBTRG-05MG cells assessed as inhibition of cell growth incubated for 72 hrs by cell counting kit method
    Antiproliferative activity against human DBTRG-05MG cells assessed as inhibition of cell growth incubated for 72 hrs by cell counting kit method
    [PMID: 38458106]
    DU-145 IC50
    11 μM
    Compound: mnd
    Antiproliferative activity against human androgen-independent prostate carcinoma DU145 cell line by colorimetric assay
    Antiproliferative activity against human androgen-independent prostate carcinoma DU145 cell line by colorimetric assay
    [PMID: 16216500]
    DU-145 IC50
    9.86 μM
    Compound: Menadione
    Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 23791367]
    GES1 IC50
    16.85 μM
    Compound: VK3
    Toxicity in human GES1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Toxicity in human GES1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35085721]
    HCT-116 IC50
    12.37 μM
    Compound: VK3
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35085721]
    HFF-1 IC50
    > 50 μM
    Compound: 3
    Cytotoxicity against HFF-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    Cytotoxicity against HFF-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
    [PMID: 34438124]
    HGC-27 IC50
    9.7 μM
    Compound: VK3
    Cytotoxicity in human HGC-27 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HGC-27 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35085721]
    HL-60 IC50
    5.6 μM
    Compound: 18
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    HL-60 IC50
    7.51 μM
    Compound: VK3
    Cytotoxicity in human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35085721]
    HT-29 IC50
    13.6 μM
    Compound: VK3
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35085721]
    HT-29 IC50
    9.69 μM
    Compound: Menadione
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 23791367]
    HaCaT IC50
    15.8 μM
    Compound: MD
    Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopic analysis
    Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopic analysis
    [PMID: 26840368]
    HaCaT IC50
    15.8 μM
    Compound: Menadione
    Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy
    Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy
    [PMID: 24964246]
    HaCaT IC50
    15.8 μM
    Compound: Menadione
    Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay
    Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay
    [PMID: 28410493]
    HaCaT IC50
    15.8 μM
    Compound: menadione
    Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
    Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy
    [PMID: 22845014]
    HeLa EC50
    3.7 μM
    Compound: Menadione
    Cytotoxicity against HeLa cell lines
    Cytotoxicity against HeLa cell lines
    [PMID: 15369400]
    HeLa IC50
    18 μM
    Compound: 1d
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 24913712]
    HeLa IC50
    24 μM
    Compound: 13
    Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells
    Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells
    [PMID: 19028102]
    HeLa IC50
    24.7 μM
    Compound: Menadione
    Cytotoxicity against human HeLa cells assessed as inhibition of formazan formation at day 6 by measuring absorbance at 430 nm
    Cytotoxicity against human HeLa cells assessed as inhibition of formazan formation at day 6 by measuring absorbance at 430 nm
    [PMID: 19969400]
    Jurkat IC50
    5 μM
    Compound: 18
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    LS174T IC50
    26.6 μM
    Compound: 18
    Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    MCF7 IC50
    9 μM
    Compound: 18
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    MDA-MB-231 IC50
    12.68 μM
    Compound: Menadione
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 23791367]
    MGC-803 IC50
    11.85 μM
    Compound: VK3
    Cytotoxicity in human MGC-803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human MGC-803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 35085721]
    MIA PaCa-2 IC50
    6.2 μM
    Compound: mnd
    Antiproliferative activity against human pancreatic carcinoma Mia PaCa2 cell line by colorimetric assay
    Antiproliferative activity against human pancreatic carcinoma Mia PaCa2 cell line by colorimetric assay
    [PMID: 16216500]
    MONO-MAC-6 IC50
    6.2 μM
    Compound: 18
    Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    N2a IC50
    2.688 μM
    Compound: Menadione
    Inhibition of reactive oxygen species production in mouse Neuro2a cells assessed as decrease in H2O2 levels after 6 hrs by ROS-Glo luminescence assay
    Inhibition of reactive oxygen species production in mouse Neuro2a cells assessed as decrease in H2O2 levels after 6 hrs by ROS-Glo luminescence assay
    [PMID: 28152427]
    PBMC IC50
    14.5 μM
    Compound: 18
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    SAS IC50
    14 μM
    Compound: 1d
    Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 24913712]
    SW982 IC50
    9.3 μM
    Compound: 18
    Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    THP-1 IC50
    6.3 μM
    Compound: 18
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    U-937 IC50
    6.3 μM
    Compound: 18
    Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
    [PMID: 31563013]
    Vero IC50
    6.5 μg/mL
    Compound: 21, menadione
    Cytotoxicity against Vero cells after 48 hrs by XTT method
    Cytotoxicity against Vero cells after 48 hrs by XTT method
    [PMID: 17888665]
    In Vitro

    Menadione (0-100 μM, 24-72 h) induces necrosis at high concentrations (100 μM) and apoptosis at low concentrations (10-20 μM) in AR4-2J cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[2]

    Cell Line: AR4-2J cells
    Concentration: 0-100 μM
    Incubation Time: 24-72 h
    Result: Inhibited cell proliferation in time- and dose-dependently manner at lower concentrations (1-20 μM).

    Western Blot Analysis[2]

    Cell Line: AR4-2J cells
    Concentration: 0-100 μM
    Incubation Time: 24 h
    Result: Induced wild-type P53 at the dose of 1-20 μM.
    Induced a low level of wild-type P53 at the dose of 100 μM.
    In Vivo

    Menadione (25-150 mg/kg, i.v., once time or every other day for five times) produces more severe lesionsin male Wister rats with a single injection than five injections [1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male Wister rats[1]
    Dosage: 25-150 mg/kg
    Administration: i.v., once time or every other day for five times
    Result: Showed microgranular degeneration of renal tubular cells at the dose of 25 mg/kg.
    Observed microgranular degeneration of renal tubular cells and mild pulmonary hemorrhage at the dose of 50 mg/kg.
    Produced lesions in the kidney, heart, liver and lung at the dose of 100-150 mg/kg.
    Showed kidney apoptosis at the dose of 100-150 mg/kg.
    Clinical Trial
    Molecular Weight

    172.18

    Formula

    C11H8O2

    CAS No.
    Appearance

    Solid

    Color

    Light yellow to green yellow

    SMILES

    O=C1C(C)=CC(C2=C1C=CC=C2)=O

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 125 mg/mL (725.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Ethanol : 9.09 mg/mL (52.79 mM; Need ultrasonic)

    H2O : 0.1 mg/mL (0.58 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 5.8079 mL 29.0394 mL 58.0788 mL
    5 mM 1.1616 mL 5.8079 mL 11.6158 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (12.08 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (12.08 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.82%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 5.8079 mL 29.0394 mL 58.0788 mL 145.1969 mL
    5 mM 1.1616 mL 5.8079 mL 11.6158 mL 29.0394 mL
    10 mM 0.5808 mL 2.9039 mL 5.8079 mL 14.5197 mL
    15 mM 0.3872 mL 1.9360 mL 3.8719 mL 9.6798 mL
    20 mM 0.2904 mL 1.4520 mL 2.9039 mL 7.2598 mL
    25 mM 0.2323 mL 1.1616 mL 2.3232 mL 5.8079 mL
    30 mM 0.1936 mL 0.9680 mL 1.9360 mL 4.8399 mL
    40 mM 0.1452 mL 0.7260 mL 1.4520 mL 3.6299 mL
    50 mM 0.1162 mL 0.5808 mL 1.1616 mL 2.9039 mL
    DMSO 60 mM 0.0968 mL 0.4840 mL 0.9680 mL 2.4199 mL
    80 mM 0.0726 mL 0.3630 mL 0.7260 mL 1.8150 mL
    100 mM 0.0581 mL 0.2904 mL 0.5808 mL 1.4520 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Menadione
    Cat. No.:
    HY-B0332
    Quantity:
    MCE Japan Authorized Agent: